Organ-on-a-Chip Resources

How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials

This blog explores a world where novel multi-organ in vitro models, tiny replicas of the human intestine and liver, provide the key to unlocking a deeper understanding of how we Absorb, Distribute and Metabolize drugs.

Read more to discover why accurately estimating human ADME remains a challenge and a potential solution that enables greater confidence in lead candidates and a reduced risk of identifying poor oral bioavailability during first in human studies.

Organ-on-a-chip Contract Research Services Brochure

Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints.

ADME Studies: Determining Promising Drug Compounds

Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

This article is taken from PharmTech, November 2022.

How to Keep Breathing – The Future of Inhaled Medication Testing

Dr Emily Richardson discusses the current challenges faced to bring inhaled therapeutics to the market and the potential of Organ-on-a-Chip to increase positive outcome by improving ADME drug testing.

This article is taken from International Biopharmaceutical Industry, Summer 2022.

PhysioMimix Multi-organ System Animation

An introduction to the CN Bio PhysioMimix Multi-organ System. This animation demonstrates how our microphysiological system works, how to create a Gut/Liver-on-a-chip model and an example of its use in determining drug Bioavailability in vitro.

Application of a gut–liver-on-a-chip device and mechanistic modeling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil

Milani et al., 2022

This study shows how an in vitro gut-liver multi-organ model can quantitatively recapitulate the in vivo metabolism of a drug. By combining Organ-on-a-chip with in silico modeling, the study also demonstrates the potential of multi-organ models for quantitative estimation of PK parameters of a drug and its metabolites.

Normalization of organ-on-a-chip samples for mass spectrometry based proteomics and metabolomics via dansylation-based assay

Gallagher et al

This poster shows the combined use of MS-based proteomics and metabolomics with organ-on-a-chip to better assess the classification of biological replicates in toxicity studies.

Harnessing the power of multimodal imaging to explore ASO distribution in cells, complex in vitro models and tissue

Alex et al

This recent poster from GSK and collaborators features data from our PhysioMimix® OOC and Liver (MPS-LC12) plates. The results demonstrate that the distribution of ASOs into Kupffer cells and circular or cuboidal hepatocytes cultured in 3D can be detected using imaging.

Exploration and Application of a Liver-on-a-Chip Device in Combination with Modelling and Simulation for Quantitative Drug Metabolism Studies

Docci et al., 2022

This publication explores the potential of the PhysioMimix liver model for investigating drug candidates for hepatic disease. This study integrates mathematical modeling with experimental liver-on-a-chip studies and demonstrates how this approach supports the generation of high-quality data from complex in vitro cellular systems.

Multiorgan microphysiological systems as tools to interrogate interorgan crosstalk and complex diseases

Trapecar, 2022

A review of the state of multi-organ microphysiological systems in 2021. Overviews of currently available multi-organ MPS and the different technologies, cells and physiological cues used. Discusses approaches for systems biology integration and how MPS can be more readily adopted in the wider research community.

Improved prediction of oral bioavailability using a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Central to the development of new drugs is an understanding of their pharmacokinetic properties, in particular their bioavailability. Here, we demonstrate the potential of a true 2-organ gut-liver MPS to better predict human bioavailability and improve in vitro to in vivo correlation.

Drug metabolism in a gut-liver microphysiological system

Abbas, Kostrzewski & Hughes

Studies investigating the efficacy and safety of candidate drugs use a variety of animal models to translate research from the bench to clinical trials and then to the clinic. Here, we demonstrate the potential of multi-organ MPS models for improved predictions of in vivo drug absorption and hepatic clearance rates.